APR
APR Applied Pharma Research s.a (APR), the Swiss developer of science driven and patent protected healthcare products, is pleased to share the success of a special event, “Test the taste”, addressed to Phenylketonuria (PKU) patients and organized with the purpose of allowing them to test the company innovative Phenylalanine (Phe)-free medical food for PKU management .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180712005363/en/
The initiative, promoted by the APMMC, the Italian patients association of inherited metabolic diseases with the unconditioned support of APR, aimed at gathering genuine feedbacks from PKU patients and their families on the company innovative medical food palatability in a friendly and relaxed setting - a Sunday lunch.
During the lunch, a well-known chef prepared, under medical supervision, a full menu suitable for a PKU diet, made of four dishes - from appetizer to dessert, each of them including APR Phe-free amino-acids (AA) supplementation.
After each course, patients and caregivers, who did not receive any information about the company innovation, were asked to assess the supplemented food just enjoyed (under medical guidance) as per texture , odor , taste and after -taste by filling out a brief questionnaire. For a complete evaluation, appetizer was served twice, with and without APR’s Phe-free AA mix, to allow the audience to better grab the differences.
Responses from both patients and families are extremely positive : no remarkable differences were reported in terms of odor and taste after sampling the appetizer with or without the AA mix.
According to the guests, APR innovative Phe-free supplementation did not affect the overall food taste and odor as the opinions expressed on the dishes served mostly referred to either the flavor or the texture of the ingredients regardless of the AA mix . The most noticeable feedback is the one regarding the aftertaste of the AA mix, which, as reported by PKU patients, could impact negatively their food experience: APR Phe-free AA mixture was markedly appreciated .
“At last thanks to APR’s new AA mix we have the chance to enjoy a delicious lunch without worrying about odor, taste and aftertaste of the supplementation.” said a patient who participated to the initiative “Food palatability was really great and we are eager to test this innovative AA mix a variety of recipes! We hope to find soon APR’s AA mix available as it can help us as patients to achieve a lasting and rewarding compliance to the compulsory dietary regimen”.
“As father of a PKU teenager and having gone through the troubles of a strict long-life dietetic treatment, we are very proud to offer to patients a new perspective of quality of life. Our dream is to make a real difference for those who live and deal with PKU.” said Paolo Galfetti, CEO of APR.
APR’s innovative and patented Physiomimic Technology® is able to remarkably mask the naturally unpleasant taste and the odor of some amino acids, offering a considerably palatable medical food , which can be easily accepted by patients, thus supporting their compliance and impacting positively their quality of life.
On the other side, as shown in a recent kinetic study, APR’s advanced formulation of AAs, by providing amino acids in more physiological manner (mimicking that of dietary proteins) , has the very encouraging potential of contributing to maintain Phe levels within the recommended ranges, with less prominent fluctuations of Phe over time, thanks to a prolonged release of AA s in the gut.
Further preclinical studies as well as clinical evidences are underway to reinforce the scientific profile of the innovative medical food.
APR will present officially its new range of Phe-free medical food for PKU dietary management, as well as new original scientific data, at the next Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism) on September 4th-7th in Athens, which will be the occasion for attendees to get to know APR’s innovation and the patented technology behind it.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005363/en/
Contact:
APR Applied Pharma Research s.a.:
Paolo Galfetti, Chief Executive
Officer
paolo.galfetti@apr.ch
+41
91 6957020
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom